SCHEMBL16887971

SCHEMBL16887971

COc1cc(O)c2c(c1)OC(c1ccc(O)c(O)c1)C(O)C2=O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.75
▸ CYP3A4 P08684 4/20 0.75
▸ ALOX15 P16050 4/20 0.75
▸ MEN1 O00255 3/20 0.75
▸ KMT2A Q03164 3/20 0.75
▸ HSD17B10 Q99714 3/20 0.75
▸ RECQL P46063 2/20 0.75
▸ POLB P06746 2/20 0.75
▸ SOST Q9BQB4 2/20 0.75
▸ KDM4E B2RXH2 2/20 0.75
▸ GAA P10253 2/20 0.75
▸ ALOX12 P18054 2/20 0.75
▸ HIF1A Q16665 2/20 0.75
▸ CYP1A2 P05177 1/20 0.75
▸ NFKB1 P19838 1/20 0.75
▸ MAPK1 P28482 1/20 0.75
▸ XDH P47989 2/20 0.68
▸ ALDH1A1 P00352 3/20 0.64
▸ SYNJ2 O15056 3/20 0.63
▸ IDO1 P14902 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23698994 1.00 MAPT (0.75) MAPTCYP3A4ALOX15MEN1KMT2A
SCHEMBL28302550 0.91 ALDH1A1 (0.71) MAPTCYP3A4ALOX15MEN1KMT2A
SCHEMBL28213500 0.91 ALDH1A1 (0.71) MAPTCYP3A4ALOX15MEN1KMT2A
SCHEMBL30641793 0.90 CBS (0.67) MAPTCYP3A4ALOX15MEN1KMT2A
SCHEMBL28684198 0.90 CBS (0.67) MAPTCYP3A4ALOX15MEN1KMT2A
SCHEMBL31190926 0.90 CBS (0.67) MAPTCYP3A4ALOX15MEN1KMT2A
(+)-Taxifolin SCHEMBL18131936 0.89 CYP3A4 (0.90) MAPTCYP3A4ALOX15MEN1KMT2A
SCHEMBL17485808 0.88 XDH (0.62) MAPTCYP3A4ALOX15MEN1KMT2A
SCHEMBL21588168 0.88 SYNJ2 (0.74) MAPTCYP3A4ALOX15MEN1KMT2A
SCHEMBL30350498 0.88 SYNJ2 (0.74) MAPTCYP3A4ALOX15MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3858155-A1 A SWEETENER OR SWEETNESS ENHANCER COMPOSITION Analyticon Discovery GmbH (DE) 2021-08-04 — — EP claimed
CN-119454690-A Application of natural compound in preparing medicine for treating or preventing central nervous system disorder and cardiovascular disease 常州大学 2025-02-18 — — CN disclosed
CN-109856264-B Method for detecting content of effective components in blumea balsamifera medicinal material 遵义医科大学 2021-09-07 — — CN disclosed
EP-3858155-A1 A SWEETENER OR SWEETNESS ENHANCER COMPOSITION Analyticon Discovery GmbH (DE) 2021-08-04 — — EP disclosed
US-20150191430-A1 CONJUGATES OF HUPERZINE AND ANALOGS THEREOF BISCAYNE NEUROTHERAPEUTICS, INC. 2015-07-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191430-A1 CONJUGATES OF HUPERZINE AND ANALOGS THEREOF HTT, HNMT, GAP43 MAPT 5/4885CYP3A4 2126/4885ALOX15 686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback